Related coverage linked through entity extraction aliases.
Mar 19, 2026
A phase IIa trial found that a single dose of DMT, the active ingredient in ayahuasca, improved depressive symptoms in adults with depression. The small, randomized study showed effects lasting up to three months, with mainly mild adverse effects. Experts call the results promising but preliminary.
Apr 12, 2026
A 34-person trial found that a single 21.5mg intravenous dose of DMT with psychotherapy produced rapid antidepressant effects lasting three to six months. Separate brain-scan research across five psychedelics found a shared pattern of weaker within-network links and stronger communication between brain networks.
Feb 17, 2026
Compass Pathways reports positive Phase 3 results for synthetic psilocybin in treatment-resistant depression, while a Phase 2 trial demonstrates rapid antidepressant effects from single-dose DMT. Both studies show modest efficacy signals amid growing pharmaceutical interest in psychedelic compounds.
